Cabazitaxel for metastatic castration-resistant prostate cancer progressing after docetaxel treatment
Bulletin du Cancer, 07/19/2012
Clinical Article
Pouessel D et al. – The results are comparable to those reported for the overall population and the safety profile remains favorable without any toxic death related to cabazitaxel.



